Navigation Links
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
Date:3/22/2013

HAYWARD, Calif., March 22, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced its abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus," has been selected as an oral presentation and will be presented at the 10th International Congress on Systemic Lupus Erythematosus by Dr. Morton Scheinberg , a rheumatologist at the Hospital Abreu Sodre Pesquisa Clinica in Sao Paulo, Brazil, on April 20, 2013.

Additionally, a poster entitled "Clinical Experience in Latin America With Blisibimod Amongst Subjects with Active, Moderate-to-Severe Systemic Lupus Erythematosus: Data From The Phase 2b PEARL-SC Study," will be presented by Dr. Scheinberg as part of the conferences Guided Poster Tours on April 19, 2013.

The poster will be available on www.anthera.com.

About Blisibimod and PEARL-SC

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF inhibitors potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a selective inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.  The PEARL-SC Phase 2 study was designed as a randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate the safety, tolerability and efficacy of blisibimod plus standard of care, versus placebo plus standard of care.  A total of 547 patients with active SLE were randomized to receive one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week treatment period, in addition to standard-of-care therapy. The study was conducted at multiple centers worldwide. 

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
2. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
3. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
9. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
10. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... 2035" report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, ... growing market of deep learning solutions within the healthcare domain. Primarily ... as a novel solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease ... hospitals in the United States, it’s a threat that is constantly changing and ... infection prevention and offers strategies for the healthcare community to help decrease the ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by ... it does not obey the rules Congress has directed the CBO to follow. The ... GOP reform would restore. Yet, it estimates a reduction in employer-based coverage due to ...
(Date:3/24/2017)... MI (PRWEB) , ... March 24, 2017 , ... ... assistance, financial planning, and related services to families and business owners across eastern ... aimed at feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH ...
(Date:3/24/2017)... ... 2017 , ... As the standards bearer of advanced cancer ... positions them as the go-to thought leader in all matters concerning oncology nursing. ... always-on, always-fresh news, views and advocacy engine, called ONS Voice. , The ONS ...
(Date:3/24/2017)... , ... March 24, 2017 , ... The law firm ... Plains, N.Y., is pleased to announce Westchester resident Lauren C. Enea has joined the ... for the firm, will concentrate her practice in elder law, Medicaid planning and applications, ...
Breaking Medicine News(10 mins):